GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Ltd (STU:IQI) » Definitions » Net Income Including Noncontrolling Interests

Incannex Healthcare (STU:IQI) Net Income Including Noncontrolling Interests : €18.64 Mil (TTM As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Incannex Healthcare Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Incannex Healthcare's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was €-5.55 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was €18.64 Mil.

Incannex Healthcare Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Incannex Healthcare's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incannex Healthcare Net Income Including Noncontrolling Interests Chart

Incannex Healthcare Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.85 -1.69 -2.87 -7.09 -9.70

Incannex Healthcare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.34 28.99 - -4.81 -5.55

Incannex Healthcare Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €18.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incannex Healthcare Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Incannex Healthcare's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Incannex Healthcare (STU:IQI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Ltd (STU:IQI) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
PNXP CYTH BGXX DRRX RMTI QLI CPIX INIS SHWZ TXMD ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX
Traded in Other Exchanges
IXHL:USA
Address
8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000
Website
https://www.incannex.com.au
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products.